Amneal Pharmaceuticals Holding Co (AMRX) Noticias

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Represents Amneal’s fourth 505(b)(2) injectable approval in 2024 Ready-to-use oncology treatment used for multiple myeloma and mantle cell...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables...

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Amneal Reports Second Quarter 2024 Financial Results

‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million;...

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Delivers more “Good On” time with less frequent dosing compared to Immediate Release CD/LD Underscores Amneal’s leadership in Parkinson’s disease...

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will...

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday...

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC...

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®) ADL018 is Kashiv’s lead pipeline biosimilar...

Amneal Releases 2023 Environmental, Social and Governance Report

Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a...

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

The Company’s leading R&D capabilities and robust, expanded manufacturing capacity are helping to address chronic market shortages Amneal...

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

Significantly expanding access to affordable, life-saving opioid overdose rescue medicine Entered distribution agreement with California;...